C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

Adult CIRB - Late Phase Emphasis Meeting Agenda

November 5, 2026

I Continuing Review

10272, A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer (Version Date 05/21/26)

II Continuing Review

A021602, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) (Version Date 07/16/25)

III Continuing Review

A021804, A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma (Version Date 01/12/26)

IV Continuing Review

EA2174, A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma (Version Date 08/06/25)

V Continuing Review

EA6134, DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial (Version Date 12/01/25)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

VI Continuing Review

EA6192, A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) (Version Date 12/11/25)

VII Continuing Review

EA7211, A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2) (Version Date 06/23/26)

VIII Continuing Review

EA9181, A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults (Version Date 07/23/26)

IX Continuing Review

EAA173, Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) (Version Date 02/23/26)

X Continuing Review

NRG-GU012, Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (Version Date 08/20/26)

XI Continuing Review

NRG-LU007, RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (Version Date 03/13/25)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XII Continuing Review

S1609, DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Version Date 07/28/25)

XIII Continuing Review

S1827, MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (Version Date 08/01/25)

XIV Continuing Review

S2005, A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib plus Rituximab or Zanubrutinib alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL) (Version Date 12/01/25)

XV Continuing Review

S2107, Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer (Version Date 07/18/25)

XVI Continuing Review

S2303, Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (Version Date 11/01/25)

C›I›R›B
FOR THE NATIONAL CANCER INSTITUTE

XVII Continuing Review

S2414, Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non-Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) (Version Date 03/11/25)